期刊文献+

治疗男性复发性尿道尖锐湿疣76例报告 被引量:1

Treatment of male recurrent urethral condyloma: report of 76 cases report
下载PDF
导出
摘要 目的探讨减少尿道尖锐湿疣复发的有效治疗方法。方法选取76例确诊为初次复发尿道尖锐湿疣的男性患者,随机分成2组:对照组物理方法(激光或电灼)除疣体后,局部外用咪奎莫特乳膏;治疗组物理方法除疣体,局部外用咪奎莫特乳膏,同时全身应用白介素-2(IL-2)和干扰素(IFN-γ),并配合生活指导。疗程为6周,均随访9月以上。结果 76例患者均完成临床研究,对照组复发率24.32%(9/37),治疗组7.69%(3/39)。2组复发率比较,差异有统计学意义(P=0.047)。不良反应发生率:局部反应(对照组12/37,治疗组15/39)两组差异无统计学意义(P=0.583),但轻微的全身不良反应及实验室检查异常者所占比例治疗组明显高于对照组(对照组1/37,治疗组13/39),两组差异有统计学意义(P=0.001)。结论物理方法除疣体,联合局部+全身免疫治疗,并配合生活指导,治疗男性复发性尿道尖锐湿疣效果满意,但是轻微的全身副反应也有所增加。 Objective To discuss the effective treatment of the recurrence of urethral condyloma acuminatum(CA).Methods 76 cases of first time CA recurrence were randomly assigned into 2 groups.Control Group: After CA was removed with physical method(laser or electrocautery),imiquimod was used locally.Therapy Group: Besides physical methods and local use of imiquimod,systemic application of interleukin-2(IL-2)and interferon(IFN-γ)were used and living style was instructed.Patients were treated for 6 weeks and followed up for over 9 months.Results All 76 patients completed the clinical research.The recurrence rates in Control Group and Therapy Group were 24.32% and 7.69%(P=0.047)respectively.No significant difference between the two groups was found in local adverse reactions(P=0.583).Howerer,systemic adverse reactions and laboratory abnormalities in Therapy Group were significantly higher than those in Control Group.Conclusion Physical excision,local and systemic immunotherapy combined with life-style instruction resulted in satisfactory effects,but minor systemic side effects also increased.
出处 《现代泌尿外科杂志》 CAS 2010年第5期373-374,398,共3页 Journal of Modern Urology
关键词 尿道尖锐湿疣 复发 咪奎莫特乳膏 免疫治疗 urethral condyloma acuminatum lesions relapse imiquimod cream,immunotherapy
  • 相关文献

参考文献6

二级参考文献23

  • 1肖嵘,王仁林,方建珍,张运昌,文海泉.尖锐湿疣患者外周血细胞免疫检测[J].中华皮肤科杂志,1995,28(3):172-172. 被引量:35
  • 2钱起丰.尖锐湿疣患者血清白介素10水平及其与白介素2关系的研究[J].中华皮肤科杂志,1996,29(3):172-174. 被引量:41
  • 3钱起丰.尖锐湿疣患者血清白介素-2及其可溶性受体的酶免疫检测[J].中国皮肤性病学杂志,1996,10(3):144-144. 被引量:51
  • 4张大宏.尿道尖锐湿疣的发病特点及治疗[J].临床泌尿外科杂志,2000,35(7).
  • 5[1]BEUTNER KR, SPRUANCE SL, HOUGHAM AJ,et al.Treatment of genital warts with an immune-response modifier(imiquimod)[J].J Am Acad Dermatol,1998,38(2Pt 1):230-239.
  • 6[2]TYRING SK.Immune response modification:imiquimod[J].Aust J Dermatol,1998,39 Suppl 1:S11-S13.
  • 7[3]BEUTNER KR, FERENCZY A.Therapeutic approaches to genital warts[J].Am J Med, 1997,102(5A):28-37.
  • 8[4]IMBERTSON LM,BEAURLINE JM, COUTURE AM,et al.Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463[J].J Invest Dermatol,1998,110(5):734-739.
  • 9[5]TYRING SK, ARANY I,STANLEY MA,et al.A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod[J].J Infect Dis,1998,178(2):551-555.
  • 10[6]ARANY I, TYRING SK, STANLEY MA,et al.Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%[J].Antiviral Res, 1999,43(1):55-63.

共引文献30

同被引文献9

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部